Rhumbline Advisers Makes New $161,000 Investment in Atossa Therapeutics, Inc. (NASDAQ:ATOS)

Rhumbline Advisers purchased a new position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 135,118 shares of the company’s stock, valued at approximately $161,000. Rhumbline Advisers owned about 0.11% of Atossa Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Cetera Advisors LLC purchased a new position in shares of Atossa Therapeutics during the 1st quarter valued at about $72,000. Vanguard Group Inc. boosted its position in shares of Atossa Therapeutics by 1.4% in the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after purchasing an additional 78,269 shares during the period. Virtu Financial LLC purchased a new stake in shares of Atossa Therapeutics in the first quarter worth $151,000. Finally, Bank of New York Mellon Corp raised its position in shares of Atossa Therapeutics by 3,160.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after purchasing an additional 399,041 shares during the period. Institutional investors own 12.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Ascendiant Capital Markets upped their target price on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a report on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Atossa Therapeutics in a research note on Monday, August 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Atossa Therapeutics in a report on Thursday, June 20th. Finally, StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 12th.

Atossa Therapeutics Stock Up 8.6 %

ATOS opened at $1.51 on Monday. Atossa Therapeutics, Inc. has a 52 week low of $0.62 and a 52 week high of $2.31. The firm has a 50-day simple moving average of $1.37 and a two-hundred day simple moving average of $1.42. The company has a market capitalization of $189.89 million, a PE ratio of -6.29 and a beta of 1.19.

Atossa Therapeutics (NASDAQ:ATOS) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. As a group, sell-side analysts expect that Atossa Therapeutics, Inc. will post -0.22 earnings per share for the current year.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.